速递|信达生物玛仕度肽15mg,启动中重度肥胖1/2期临床

GLP1减重宝典
Yesterday

整理 | GLP1减重宝典内容团队2025年6月3日,信达生物在Clinicaltrials.gov网站上注册了IBI362(玛仕度肽)治疗中至重度肥胖的1/2期临床试验。该1/2期临床试验计划入组98例中至重度肥胖患者,预计2026年12月初步完成。该1/2期临床以替尔泊肽作为阳性对照组。入组标准为中至重度肥胖患者,即BMI在32.5以上的患者。*来源:信达生物

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10